Real-World Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Standard of Care: A Cota Database Analysis

弥漫性大B细胞淋巴瘤 医学 耐火材料(行星科学) 淋巴瘤 护理标准 内科学 数据库 生物 计算机科学 天体生物学
作者
Andrew Ip,Alex Mutebi,Tongsheng Wang,Monika Jun,Anupama Kalsekar,Fernando Rivas Navarro,Anthony Wang,Rajesh Kamalakar,Mariana Sacchi,Brian Elliott
出处
期刊:Blood [American Society of Hematology]
卷期号:140 (Supplement 1): 6693-6694 被引量:1
标识
DOI:10.1182/blood-2022-159569
摘要

Introduction: Despite the rapidly evolving therapeutic landscape for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treatment with chemotherapy, single-agent rituximab/obinutuzumab, single-agent lenalidomide, or combinations of these agents are common components of R/R DLBCL treatment regimens. This study aimed to characterize clinical outcomes in a real-world cohort of patients with R/R DLBCL treated with the above SOC regimens in the second-line or later setting and to assess the impact of patient demographics and clinical characteristics on clinical outcomes. Methods: This retrospective, observational study used data from the COTA electronic health records database (COTA, New York, NY). The study included adults diagnosed with DLBCL between January 1, 2010, and March 31, 2022, treated with ≥ 1 prior systemic line of therapy (LOT), including ≥ 1 anti-CD20 monoclonal antibody-containing regimen. Patients had an evaluable response assessment for these R/R DLBCL treatment regimens: chemotherapy, single-agent rituximab/obinutuzumab, single-agent lenalidomide, or combinations of these agents. Treatment outcomes were evaluated using real-world overall response rate (rwORR), real-world complete response (rwCR) rate, real-world duration of response (rwDOR), real-world duration of complete response (rwDOCR) rate, real-world progression-free survival (rwPFS), and overall survival. Subgroup analyses were conducted for patients with ≥ 2 prior LOTs. Logistic regression and Cox proportional hazards regression analyses evaluated the association between outcomes and patient demographics and clinical characteristics. Results: Overall, 573 patients with R/R DLBCL who had ≥ 1 prior LOT were included in the study; of these, 179 patients (31.2%) had ≥ 2 prior LOTs. Median duration of follow-up was 7.7 months. More than one-half (57.1%) were men; 49.9% were aged > 65 years (aged > 75 years, 20.8%) at diagnosis; 82.0% had an ECOG performance status of 0 to 1; 2.8% had prior exposure to chimeric antigen receptor T-cell (CAR T) therapy; 7.0% had prior autologous stem cell transplant; 62.0% had primary refractory disease; 68.6% were refractory to their last LOT; and 67.7% were refractory to their most recent anti-CD20 therapy. Patients experienced worsening outcomes as they progressed through LOTs. In patients with ≥ 1 prior LOT, rwORR was 52% (95% CI: 48-56), rwCR rate was 23% (95% CI: 19-27), median rwPFS was 3.0 (95% CI: 2.8-3.3) months, and median overall survival (mOS) was 12.9 (95% CI: 10.1-16.9) months. In the subgroup with ≥ 2 prior LOTs, rwORR was 40% (95% CI: 33-48), rwCR rate was 13% (95% CI: 8-19), median rwPFS was 2.4 (95% CI: 2.0-2.7) months, and mOS was 6.2 (95% CI: 5.2-10.9) months. In patients with ≥ 3 prior LOTs, rwORR was 34% (95% CI: 23-45), rwCR rate was 8% (95% CI: 3-16), rwDOR was 2.3 (95% CI: 1.3-3.3) months, rwDOCR was 8.5 (95% CI: 2.1-not estimable) months, median rwPFS was 1.9 (95% CI: 1.5-2.5) months, and mOS was 5.1 (95% CI: 3.2-7.3) months. Factors consistently associated with worse efficacy outcomes were primary refractory disease, refractory to last LOT, and refractory to last anti-CD20 therapy (Table). These characteristics indicated elements of a patient population with difficult-to-treat R/R DLBCL, with a 48%-66% lower likelihood of achieving a rwORR; a 45%-101% higher risk of progression; and a 39%-111% higher risk of mortality than those without these characteristics. Discussion: Patients with R/R DLBCL who received an increasing number of prior LOTs, had primary refractory disease, were refractory to their last LOT, were refractory to their last anti-CD20 therapy, or had prior exposure to CAR T therapy had poor outcomes, with an rwORR (rwCR rate) of 40% (13%) and 34% (8%) in patients with ≥ 2 prior LOTs and ≥ 3 prior LOTs, respectively. This is consistent with prior retrospective analyses of pretreated DLBCL (Crump et al, Blood 2017; Hamadani et al, Clin Lymphoma Myeloma Leuk 2022). Conclusions: Outcomes in patients with R/R DLBCL treated with chemotherapy, single-agent rituximab/obinutuzumab, single-agent lenalidomide, or combinations of these agents remain poor, especially those with difficult-to-treat R/R DLBCL. These findings underscore the high unmet need for new, safe, and effective therapies across this population, including the difficult-to-treat R/R DLBCL subgroups. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
磕学家完成签到 ,获得积分10
1秒前
磕学家关注了科研通微信公众号
11秒前
woshiwuziq完成签到 ,获得积分10
12秒前
ovood完成签到 ,获得积分10
15秒前
19秒前
月亮完成签到 ,获得积分10
23秒前
zodiac完成签到,获得积分10
24秒前
诸沧海发布了新的文献求助10
25秒前
上善若水呦完成签到 ,获得积分10
28秒前
大力小萱完成签到,获得积分10
35秒前
美满的皮卡丘完成签到 ,获得积分10
38秒前
Hank完成签到 ,获得积分10
41秒前
搜集达人应助大力小萱采纳,获得10
44秒前
每天学习一点点完成签到 ,获得积分10
45秒前
先锋完成签到 ,获得积分10
51秒前
蓝桉完成签到 ,获得积分10
54秒前
林沐发布了新的文献求助10
59秒前
搜集达人应助磕学家采纳,获得10
1分钟前
1分钟前
复杂的方盒完成签到 ,获得积分10
1分钟前
czj完成签到 ,获得积分10
1分钟前
水晶李完成签到 ,获得积分10
1分钟前
fang完成签到,获得积分10
1分钟前
莫小烦完成签到,获得积分10
1分钟前
大力小萱给大力小萱的求助进行了留言
1分钟前
会撒娇的凝琴完成签到,获得积分10
1分钟前
猫与鱼完成签到 ,获得积分10
1分钟前
roundtree完成签到 ,获得积分0
1分钟前
苏晓醒完成签到,获得积分10
1分钟前
yy完成签到 ,获得积分10
1分钟前
刻苦的新烟完成签到 ,获得积分10
1分钟前
林沐发布了新的文献求助10
1分钟前
留胡子的丹彤完成签到 ,获得积分10
1分钟前
怕孤独的乌龟完成签到 ,获得积分10
1分钟前
share完成签到 ,获得积分10
2分钟前
超级的妙晴完成签到 ,获得积分10
2分钟前
CAST1347完成签到,获得积分10
2分钟前
是我不得开心妍完成签到 ,获得积分10
2分钟前
mengmenglv完成签到 ,获得积分10
2分钟前
小西完成签到 ,获得积分10
2分钟前
高分求助中
Sustainability in Tides Chemistry 1500
Handbook of the Mammals of the World – Volume 3: Primates 805
拟南芥模式识别受体参与调控抗病蛋白介导的ETI免疫反应的机制研究 550
Gerard de Lairesse : an artist between stage and studio 500
Digging and Dealing in Eighteenth-Century Rome 500
Queer Politics in Times of New Authoritarianisms: Popular Culture in South Asia 500
Manual of Sewer Condition Classification 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3068290
求助须知:如何正确求助?哪些是违规求助? 2722176
关于积分的说明 7476094
捐赠科研通 2369177
什么是DOI,文献DOI怎么找? 1256228
科研通“疑难数据库(出版商)”最低求助积分说明 609524
版权声明 596835